Schizophrenia patients with a metabolically abnormal obese phenotype have milder negative symptoms.
Metabolic syndrome
Metabolically abnormal obese
Metabolically healthy normal-weight
Negative symptoms
Schizophrenia
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
18 08 2020
18 08 2020
Historique:
received:
21
01
2020
accepted:
05
08
2020
entrez:
20
8
2020
pubmed:
20
8
2020
medline:
30
12
2020
Statut:
epublish
Résumé
Schizophrenia patients with a metabolically abnormal obese (MAO) phenotype have been shown poor cardiovascular outcomes, but the characteristics of their current psychiatric symptoms have not been characterized. This study mainly explored the psychiatric symptoms of schizophrenia patients with the MAO phenotype. A total of 329 patients with schizophrenia and 175 sex- and age-matched people without schizophrenia from Anhui Province in China were enrolled. The Positive and Negative Syndrome Scale (PANSS) was used to evaluate the mental symptoms of the schizophrenia patients. The MAO phenotype was defined as meeting 1-4 metabolic syndrome criteria (excluding waist circumference) and having a body mass index (BMI) ≥ 28 kg/m Overall, 15.8% of the schizophrenia patients and 9.1% of the control group were consistent with the MAO phenotype, and the prevalence of MAO in the schizophrenia group was higher than that in the control group. Among the patients with schizophrenia, the MAO group had lower negative factor, cognitive factor and total PANSS scores than the MHNW group. However, when confounding factors were controlled, only the negative factor remained lower significantly. We found that schizophrenia patients with the MAO phenotype had reduced negative symptoms, which may indicate an internal mechanism linking metabolic disorders and negative symptoms. This study was registered in the China Clinical Trial Registration Center (No. chiCTR 1,800,017,044 ).
Sections du résumé
BACKGROUND
Schizophrenia patients with a metabolically abnormal obese (MAO) phenotype have been shown poor cardiovascular outcomes, but the characteristics of their current psychiatric symptoms have not been characterized. This study mainly explored the psychiatric symptoms of schizophrenia patients with the MAO phenotype.
METHODS
A total of 329 patients with schizophrenia and 175 sex- and age-matched people without schizophrenia from Anhui Province in China were enrolled. The Positive and Negative Syndrome Scale (PANSS) was used to evaluate the mental symptoms of the schizophrenia patients. The MAO phenotype was defined as meeting 1-4 metabolic syndrome criteria (excluding waist circumference) and having a body mass index (BMI) ≥ 28 kg/m
RESULTS
Overall, 15.8% of the schizophrenia patients and 9.1% of the control group were consistent with the MAO phenotype, and the prevalence of MAO in the schizophrenia group was higher than that in the control group. Among the patients with schizophrenia, the MAO group had lower negative factor, cognitive factor and total PANSS scores than the MHNW group. However, when confounding factors were controlled, only the negative factor remained lower significantly.
CONCLUSION
We found that schizophrenia patients with the MAO phenotype had reduced negative symptoms, which may indicate an internal mechanism linking metabolic disorders and negative symptoms.
TRIAL REGISTRATION
This study was registered in the China Clinical Trial Registration Center (No. chiCTR 1,800,017,044 ).
Identifiants
pubmed: 32811450
doi: 10.1186/s12888-020-02809-4
pii: 10.1186/s12888-020-02809-4
pmc: PMC7437037
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
410Subventions
Organisme : National Natural Science Foundation of China
ID : 81771449
Pays : International
Organisme : Key Research and Development Projects in Anhui Province
ID : 1804h08020263
Pays : International
Organisme : Scientific Research Foundation of the Institute for Translational Medicine
ID : 2017zhyx17
Pays : International
Références
Diabetes Care. 2013 Apr;36(4):1047-55
pubmed: 23520370
Biomed Environ Sci. 2002 Mar;15(1):83-96
pubmed: 12046553
J Psychosoc Nurs Ment Health Serv. 2018 Apr 1;56(4):28-37
pubmed: 29328360
Med J Aust. 2017 Feb 6;206(2):91-95
pubmed: 28152356
JAMA Psychiatry. 2015 Dec;72(12):1172-81
pubmed: 26509694
Ann Med. 2006;38(1):42-51
pubmed: 16448988
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
J Am Coll Cardiol. 2017 Sep 19;70(12):1429-1437
pubmed: 28911506
BMC Psychiatry. 2014 Jun 20;14:184
pubmed: 24947974
Diabetes Metab Syndr. 2016 Apr-Jun;10(2 Suppl 1):S68-71
pubmed: 26951993
Acta Psychiatr Scand. 2011 Jun;123(6):423-30
pubmed: 21219266
Eur Psychiatry. 2017 Sep;45:97-103
pubmed: 28753464
Circulation. 2002 Oct 15;106(16):2137-42
pubmed: 12379586
Annu Rev Clin Psychol. 2014;10:425-48
pubmed: 24313570
Nat Rev Endocrinol. 2011 Oct 18;8(2):114-26
pubmed: 22009159
Expert Opin Pharmacother. 2017 Dec;18(17):1799-1809
pubmed: 29141463
Int J Obes (Lond). 2016 Oct;40(10):1541-1549
pubmed: 27339604
Schizophr Res. 2012 May;137(1-3):246-50
pubmed: 22356801
Eur Neuropsychopharmacol. 2015 Jan;25(1):1-16
pubmed: 25523882
BMJ. 2011 Sep 13;343:d5422
pubmed: 21914766
Pflugers Arch. 2017 Apr;469(3-4):385-396
pubmed: 28233125
Eur Psychiatry. 2014 Mar;29(3):167-71
pubmed: 23769679
Front Psychiatry. 2019 Apr 23;10:251
pubmed: 31065243
Diabetes Care. 2007 Aug;30(8):2145-7
pubmed: 17507694
J Clin Psychiatry. 2015 Oct;76(10):e1277-84
pubmed: 26528650
BMC Psychiatry. 2018 Sep 10;18(1):290
pubmed: 30200923
Diabetes Care. 2009 Dec;32(12):2297-9
pubmed: 19729521
Pharmacol Ther. 2010 Sep;127(3):210-51
pubmed: 20493213
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Adv Nutr. 2015 Jul 15;6(4):474-86
pubmed: 26178031
Eur Heart J. 2013 Feb;34(5):389-97
pubmed: 22947612
NPJ Schizophr. 2016 Jun 15;2:16020
pubmed: 27430009
Diabetes Metab. 2004 Dec;30(6):569-72
pubmed: 15671927
Diabetes Metab. 2014 Dec;40(6):423-30
pubmed: 25451190
Schizophr Res. 2018 Feb;192:69-74
pubmed: 28412089
Circ Res. 2016 May 27;118(11):1752-70
pubmed: 27230640
Brain Cogn. 2016 Dec;110:112-119
pubmed: 26525096
CNS Drugs. 2005;19 Suppl 1:1-93
pubmed: 15998156
Trends Mol Med. 2011 Feb;17(2):97-107
pubmed: 21185230
Atherosclerosis. 2015 Oct;242(2):399-406
pubmed: 26277632
Drugs Aging. 2014 Mar;31(3):159-84
pubmed: 24477569
Br J Psychiatry. 2010 Feb;196(2):116-21
pubmed: 20118455
Biomark Med. 2012 Feb;6(1):35-52
pubmed: 22296195
Diabetologia. 1998 Apr;41(4):369-79
pubmed: 9562340
JAMA Psychiatry. 2015 Dec;72(12):1243-51
pubmed: 26558708
Lancet. 2019 Sep 14;394(10202):939-951
pubmed: 31303314
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Asia Pac J Clin Nutr. 2009;18(2):240-50
pubmed: 19713184
Metabolism. 2001 Dec;50(12):1499-504
pubmed: 11735101
Int J Obes Relat Metab Disord. 1999 Feb;23(2):116-25
pubmed: 10078844
Prog Cardiovasc Dis. 2015 Jul-Aug;58(1):76-86
pubmed: 25959452